Posted On: 08/26/2015 10:47:05 PM
Post# of 30066
Quote:
Shall we add MSPrecise next or Alzheimer Diagnostics?
Let's do both together. Keep in mind I am not making up numbers, using the back of a napkin or a single source for valuation.
Quote:
Taken together, MSPrecise and LymPro may not be your traditional therapeutic drug blockbusters, but the amount of money they are designed to save both insurance companies and patients in terms of false positives far exceeds the $1B annual blockbuster threshold. With CLIA approval expected this year for both and sales beginning this quarter for LymPro and next year for MSPrecise, the prospect of a significant revaluation for Amarantus from today’s $60M seems relatively decent.
http://biotechstocks.com/inside-amarantuss-10...spotlight/
(0)
(0)
